Protalix biotherapeutics, inc. (PLX)
Income statement / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
REVENUES

-

-

-

-

-

-

-

-

-

-

-

-

-

7,118

3,784

3,351

4,364

0

0

0

-

-

3,289

3,128

0

9,288

10,728

34,577

34,870

36,060

33,468

8,119

8,386

9,208

9,217

0

0

0

REVENUES

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

COMPANY'S SHARE IN COLLABORATION AGREEMENT

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

COMPANY'S SHARE IN COLLABORATION AGREEMENT

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

1,151

1,742

87

-446

-995

-2,896

-7,423

-5,418

-4,810

-5,103

0

0

0

COST OF GOODS SOLD

10,895

10,223

8,935

8,423

9,302

8,578

12,727

16,067

15,231

15,629

13,811

9,963

8,398

6,446

2,421

971

730

-6,116

-4,541

-3,161

630

3,600

3,389

3,102

0

5,054

5,834

7,795

8,144

7,361

5,214

2,067

1,525

0

0

0

-

0

GROSS PROFIT (LOSS)

-

-

-

-

-

-

-

-

-

-

-

-

-

672

1,363

2,380

3,634

227

1,023

993

2,893

-215

-352

313

0

5,385

6,636

26,869

26,280

27,704

25,358

-1,371

1,443

3,268

3,204

0

0

0

RESEARCH AND DEVELOPMENT EXPENSES

44,693

45,725

45,796

39,949

35,534

34,614

31,661

33,489

32,170

29,101

28,336

29,045

30,412

31,398

30,113

26,123

24,889

21,263

24,247

25,300

27,352

29,038

28,709

29,623

29,225

32,415

33,018

35,572

36,665

36,864

37,878

36,102

37,818

34,993

36,000

0

0

0

Less - grants

-

-

0

1,364

-

-

2,598

2,841

3,336

3,549

4,117

5,833

5,804

6,091

5,910

5,045

4,864

2,555

3,386

4,171

5,128

3,310

3,449

2,867

3,213

8,370

8,247

8,404

7,976

7,077

6,563

0

-

0

0

-

-

-

less - grants and reimbursements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

RESEARCH AND DEVELOPMENT EXPENSES, NET

-

-

44,667

38,585

-

-

29,063

30,648

28,834

25,552

24,219

23,212

24,608

25,307

24,203

21,078

20,025

18,708

20,861

21,129

22,224

25,728

25,260

26,756

26,012

24,045

24,771

27,168

28,689

29,597

31,152

29,616

31,043

27,054

28,634

0

0

0

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

9,899

9,057

10,558

10,648

10,916

12,087

10,835

11,491

11,530

11,328

10,506

9,898

9,356

7,508

7,657

7,452

7,279

7,925

7,774

7,339

9,228

9,275

9,043

9,659

8,051

0

0

0

-

-

-

-

-

-

-

-

-

-

GENERAL AND ADMINISTRATIVE EXPENSES

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,970

8,276

6,571

6,931

6,735

6,474

0

0

0

OPERATING LOSS

-10,717

-16,589

-18,786

-19,691

-19,308

-25,218

-29,242

-33,303

-34,517

-33,655

-32,538

-31,664

-33,163

-32,143

-30,497

-26,150

-23,670

-26,406

-27,612

-27,475

-28,559

-35,218

-34,655

-36,102

-34,063

-27,135

-27,050

-10,536

-12,172

-10,863

-14,070

-37,558

-36,531

-30,521

-31,904

0

0

0

FINANCIAL EXPENSES

7,966

7,738

7,499

7,385

7,685

6,737

8,606

9,858

9,725

10,289

7,519

5,375

4,192

3,621

3,741

3,482

3,735

4,124

4,945

5,177

4,935

4,551

2,831

1,966

1,065

0

0

0

-

-

-

-

-

-

-

-

-

-

FINANCIAL INCOME

407

326

522

594

536

-1,048

-1,270

-1,305

188

1,656

1,916

1,972

589

641

390

337

123

-5

27

186

196

463

443

307

391

0

0

0

-

-

-

-

-

-

-

-

-

-

LOSS FROM CHANGE IN FAIR VALUE OF CONVERTIBLE NOTES EMBEDDED DERIVATIVE

-

-

-

-

-

-

-

-

-38,061

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

FINANCIAL EXPENSES - NET

-7,559

-7,412

-6,977

-6,791

-7,149

-9,110

-11,201

1,772

-48,923

-39,104

-36,074

-48,134

3,987

-2,980

-3,351

-3,145

-3,612

-4,129

-4,918

-4,991

-4,739

-4,088

-2,388

-1,659

-674

144

268

0

-

0

0

-

-

-

-

-

-

-

LOSS FROM CONTINUING OPERATIONS

-

-

-

-

-

-

-

-

-

-

-

-

-29,176

-35,123

-33,848

-29,295

-27,282

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

LOSS FROM DISCONTINUED OPERATIONS

-

-

-

-

-

-

-

-

-

-

-

-

-189

81,282

83,477

84,706

85,319

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

FINANCIAL INCOME - NET

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

431

648

0

0

0

NET LOSS FOR THE YEAR

-18,276

-24,001

-25,763

-26,482

-26,457

-34,328

-40,443

-31,531

-83,440

-72,759

-68,612

-79,915

-29,365

46,159

49,629

55,411

58,037

-23,332

-27,522

-28,570

-29,943

-32,359

-30,096

-30,814

-27,790

-26,782

-26,514

-10,035

-11,618

-10,654

-14,050

-37,381

-36,529

-30,090

-31,256

0

0

0

NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED

-1.11

-0.02

-0.05

-0.05

-1.65

-0.04

-0.06

-0.05

-

-0.09

-

-0.48

-

-0.07

-

-0.09

0.76

-0.04

-0.05

-0.06

-0.24

-0.09

-0.07

0.08

-0.22

-0.06

-0.07

0.05

-

0.06

-

0.07

-

-0.10

-

0.06

0.03

0.12

(Loss) earnings from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Earnings from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.07

-

-0.09

-0.10

-0.06

-0.06

-0.07

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

0.86

0.02

0.01

0.01

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (loss) earnings per share of common stock

-

-

-

-

-

-

-

-

-

-

0.00

-

-

-

-0.11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.11

-

-

-

-0.16

-

-

-

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Earnings from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share of common stock

-

-

-

-

-

-

-

-

-

-

-0.06

-

-

-

-0.11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.10

-

-

-

-0.16

-

-

-

WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE-BASIC AND DILUTED

-148,619,710

148,382

148,382

148,382,299

-145,541,959

148,187

146,644

145,305,982

-

132,549

-

124,467

-

99,821

-

99,715

98,909

93,943

93,635

93,200

93,088

92,971

92,820

92,686

92,557

92,433

92,297

92,184

-

91,929

-

87,821

-

85,585

-

-

-

-

BASIC

-

-

-

-

-

-

-

-

-

-

127,523

-

-

-

99,758

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

91,526

-

-

-

85,579

-

-

-

DILUTED

-

-

-

-

-

-

-

-

-

-

192,598

-

-

-

99,758

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

94,881

-

-

-

85,579

-

-

-

WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE of common stock, basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

81,744

80,914

80,872

Goods [Member]
REVENUES

15,866

13,842

9,379

7,955

8,978

9,691

16,554

20,906

19,242

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License and R&D Services [Member]
REVENUES

38,827

33,445

35,995

30,010

25,262

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-